Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients

被引:90
|
作者
Dubois, V
Dutronc, H
Lafon, ME
Poinsot, V
Pellegrin, JL
Ragnaud, JM
Ferrer, AM
Fleury, HJA
机构
[1] UNIV BORDEAUX 2,VIROL LAB,INST FEDERAT RECH PATHOL INFECT,F-33076 BORDEAUX,FRANCE
[2] CTR HOSP UNIV,HOP PELLEGRIN,SERV MED INTERNE,BORDEAUX,FRANCE
[3] CTR HOSP UNIV,HOP PELLEGRIN,SERV PATHOL INFECT,BORDEAUX,FRANCE
[4] CTR HOSP UNIV,HOP HAUT LEVEQUE,SERV MED INTERNE,BORDEAUX,FRANCE
[5] CTR HOSP UNIV,HOP HAUT LEVEQUE,SERV PATHOL INFECT,BORDEAUX,FRANCE
[6] ETAB TRANSFUS SANGUINE AQUITAINE,BORDEAUX,FRANCE
关键词
D O I
10.1128/JCM.35.9.2288-2292.1997
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
JC virus (JCV) acts as an opportunistic virus in immunocompromised human immunodeficient virus type 1 (HIV-1)-infected patients, The role of peripheral blood cells in central nervous system invasion, before the onset of progressive multifocal leukoencephalopathy (PML, remains controversial, In order to clarify JCV latency or reactivation status in peripheral blood, 72 HIV-1-infected patients were studied, together with 7 HIV-1-positive PML patients and 50 blood donors, Blood leukocytes, plasma, and B lymphocytes were investigated by two complementary DNA amplification procedures within the early T and late VP1 JCV genes and two reverse transcription techniques for the detection of corresponding early transcripts and mRNAs. JCV DNA was detected in 40.3% of the HIV-1-infected patients but only 8% of the blood donors (P < 0.001), Leukocytes represented 82.7% of the positive samples, but plasma from 12 patients (41.4%) contained JCV DNA. B lymphocytes seemed to be involved in the natural history of JCV but did not represent the unique cell target, JCV DNA was intermittently found in blood, and JCV mRNAs for VPI capsid protein were detected exclusively in one PML patient. Such observations demonstrate that JCV, when detected in blood, does-not undergo active multiplication. They support the JCV hematogenous spread hypothesis, but do not indicate any direct link between peripheral virus and dissemination in the central nervous system at the time of immunodepression.
引用
收藏
页码:2288 / 2292
页数:5
相关论文
共 50 条
  • [41] Osteonecrosis of the femoral head in a human immunodeficiency virus type 1-infected patient with lipodystrophy
    Tsai, YC
    Liu, CH
    Liao, CH
    Chen, MY
    Hung, CC
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2002, 101 (03) : 210 - 213
  • [42] Pulmonary Mycobacterium sherrisii infection in a human immunodeficiency virus type 1-infected patient
    Gämperli, A
    Bosshard, PP
    Sigrist, T
    Brändli, O
    Wildermuth, S
    Weber, R
    Mueller, NJ
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 4283 - 4285
  • [43] Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children
    Luzuriaga, K
    Bryson, Y
    McSherry, G
    Robinson, J
    Stechenberg, B
    Scott, G
    Lamson, M
    Cort, S
    Sullivan, JL
    JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04): : 713 - 721
  • [44] Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children
    Kalyesubula, I
    MusokeMudido, P
    Marum, L
    Bagenda, D
    Aceng, E
    Ndugwa, C
    Olness, K
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (09) : 876 - 881
  • [45] Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children
    Burger, DM
    van Rossum, AMC
    Hugen, PWH
    Suur, MH
    Hartwig, NG
    Geelen, SPM
    Scherpbier, HJ
    Hoetelmans, RMW
    Vulto, AG
    de Groot, R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 701 - 705
  • [46] STREPTOCOCCUS-PNEUMONIAE IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED CHILDREN
    GESNER, M
    DESIDERIO, D
    KIM, M
    KAUL, A
    LAWRENCE, R
    CHANDWANI, S
    POLLACK, H
    RIGAUD, M
    KRASINSKI, K
    BORKOWSKY, W
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (08) : 697 - 703
  • [47] Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects
    Veronese, FD
    Arnott, D
    Barnaba, V
    Loftus, DJ
    Sakaguchi, K
    Thompson, CB
    Salemi, S
    Mastroianni, C
    Sette, A
    Shabanowitz, J
    Hunt, DF
    Appella, E
    JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06): : 2509 - 2516
  • [48] In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients
    Lucey, DR
    Pinto, LA
    Bethke, FR
    Rusnak, J
    Melcher, GP
    Hashemi, FN
    Landay, AL
    Kessler, HA
    Paxton, RJ
    Grabstein, K
    Shearer, GM
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (01) : 43 - 48
  • [49] Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy
    Banic, S
    Koren, S
    Tomazic, J
    Vidmar, L
    Ihan, A
    Poljak, M
    Avsic-Zupanc, A
    ACTA VIROLOGICA, 2001, 45 (01) : 39 - 44
  • [50] Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients
    Goujard, C
    Vincent, I
    Meynard, JL
    Choudet, N
    Bollens, D
    Rousseau, C
    Demarles, D
    Gillotin, C
    Bidault, R
    Taburet, AM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) : 118 - 123